Diagnostic and prognostic potentials of AK126393 in bladder cancer.

Q2 Medicine Journal of Buon Pub Date : 2021-07-01

Yawei Guan, Guohui Zhang, Zhihui Li, Xin Ai, Zhuomin Jia, Jingfei Teng

{"title":"Diagnostic and prognostic potentials of AK126393 in bladder cancer.","authors":"Yawei Guan, Guohui Zhang, Zhihui Li, Xin Ai, Zhuomin Jia, Jingfei Teng","doi":"","DOIUrl":null,"url":null,"abstract":"Purpose: To elucidate the diagnostic and prognostic potentials of lncRNA AK126393 in bladder cancer.Methods: The expression levels of AK126393 in 60 matched bladder cancer tissues and paracancerous tissues were determined. In addition, AK126393 level in bladder cancer patients with different tumor staging (stage I-II and stage III-IV) was detected as well. Receiver operating characteristic (ROC) was introduced for assessing the diagnostic potential of AK126393 in bladder cancer. Based on the cut-off value of AK126393 in the enrolled 60 bladder cancer patients, they were assigned into high and low expression groups, respectively. Correlation between AK126393 level and pathological indexes of bladder cancer patients was analyzed by chi-square test. By collecting 5-year follow-up data, Kaplan-Meier method was conducted to evaluate survival influenced by AK126393. Moreover, Cox regression model was applied for analyzing potential factors affecting the prognosis of bladder cancer patients.Results: AK126393 was downregulated in bladder cancer tissues than in paracancerous ones. Its level remained lower in bladder cancer patients with stage III-IV relative to those with stage I-II. ROC illustrated the diagnostic potential of AK126393 in bladder cancer (AUC=0.8647, diagnosis threshold=2.03, sensitivity=76.7%, specificity=96.7%, Youden index=0.734). Besides, lower level of AK126393 was observed in bladder cancer patients with stage III-IV, lymph node metastasis or high-level differentiation. Kaplan-Meier curves demonstrated worse prognosis in bladder cancer patients expressing low level of AK126393. Cox regression analysis showed that AK126393 level, TNM staging, lymph node metastasis and tumor differentiation were independent risk factors influencing the prognosis of bladder cancer.Conclusions: AK126393 is downregulated in bladder cancer and closely linked to high rate of metastasis, advanced stage and poor prognosis. AK126393 may serve as diagnostic and prognostic hallmark in bladder cancer.","PeriodicalId":50248,"journal":{"name":"Journal of Buon","volume":" ","pages":"1504-1508"},"PeriodicalIF":0.0000,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Buon","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To elucidate the diagnostic and prognostic potentials of lncRNA AK126393 in bladder cancer.

Methods: The expression levels of AK126393 in 60 matched bladder cancer tissues and paracancerous tissues were determined. In addition, AK126393 level in bladder cancer patients with different tumor staging (stage I-II and stage III-IV) was detected as well. Receiver operating characteristic (ROC) was introduced for assessing the diagnostic potential of AK126393 in bladder cancer. Based on the cut-off value of AK126393 in the enrolled 60 bladder cancer patients, they were assigned into high and low expression groups, respectively. Correlation between AK126393 level and pathological indexes of bladder cancer patients was analyzed by chi-square test. By collecting 5-year follow-up data, Kaplan-Meier method was conducted to evaluate survival influenced by AK126393. Moreover, Cox regression model was applied for analyzing potential factors affecting the prognosis of bladder cancer patients.

Results: AK126393 was downregulated in bladder cancer tissues than in paracancerous ones. Its level remained lower in bladder cancer patients with stage III-IV relative to those with stage I-II. ROC illustrated the diagnostic potential of AK126393 in bladder cancer (AUC=0.8647, diagnosis threshold=2.03, sensitivity=76.7%, specificity=96.7%, Youden index=0.734). Besides, lower level of AK126393 was observed in bladder cancer patients with stage III-IV, lymph node metastasis or high-level differentiation. Kaplan-Meier curves demonstrated worse prognosis in bladder cancer patients expressing low level of AK126393. Cox regression analysis showed that AK126393 level, TNM staging, lymph node metastasis and tumor differentiation were independent risk factors influencing the prognosis of bladder cancer.

Conclusions: AK126393 is downregulated in bladder cancer and closely linked to high rate of metastasis, advanced stage and poor prognosis. AK126393 may serve as diagnostic and prognostic hallmark in bladder cancer.

微信好友朋友圈 QQ好友复制链接

本刊更多论文

AK126393在膀胱癌中的诊断和预后潜力。

目的:探讨lncRNA AK126393在膀胱癌中的诊断和预后价值。方法:检测60例配对的膀胱癌组织及癌旁组织中AK126393的表达水平。此外，我们还检测了不同肿瘤分期(I-II期和III-IV期)膀胱癌患者中AK126393的水平。引入受试者工作特征(Receiver operating characteristic, ROC)评价AK126393在膀胱癌中的诊断潜力。根据入选的60例膀胱癌患者中AK126393的截止值，将其分为高表达组和低表达组。采用卡方检验分析AK126393水平与膀胱癌患者病理指标的相关性。通过收集5年随访资料，采用Kaplan-Meier法评价AK126393对患者生存的影响。并应用Cox回归模型分析影响膀胱癌患者预后的潜在因素。结果:与癌旁组织相比，AK126393在膀胱癌组织中表达下调。相对于I-II期膀胱癌患者，III-IV期膀胱癌患者的其水平仍然较低。ROC显示AK126393在膀胱癌中的诊断潜力(AUC=0.8647，诊断阈值=2.03，敏感性=76.7%，特异性=96.7%，约登指数=0.734)。此外，在III-IV期、淋巴结转移或高分化的膀胱癌患者中，AK126393表达水平较低。Kaplan-Meier曲线显示，低水平表达AK126393的膀胱癌患者预后较差。Cox回归分析显示，AK126393水平、TNM分期、淋巴结转移及肿瘤分化是影响膀胱癌预后的独立危险因素。结论:AK126393在膀胱癌中表达下调，与膀胱癌的高转移率、晚期和不良预后密切相关。AK126393可作为膀胱癌的诊断和预后标志。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Buon 医学-肿瘤学

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： JBUON aims at the rapid diffusion of scientific knowledge in Oncology. Its character is multidisciplinary, therefore all aspects of oncologic activities are welcome including clinical research (medical oncology, radiation oncology, surgical oncology, nursing oncology, psycho-oncology, supportive care), as well as clinically-oriented basic and laboratory research, cancer epidemiology and social and ethical aspects of cancer. Experts of all these disciplines are included in the Editorial Board. With a rapidly increasing body of new discoveries in clinical therapeutics, the molecular mechanisms that contribute to carcinogenesis, advancements in accurate and early diagnosis etc, JBUON offers a free forum for clinicians and basic researchers to make known promptly their achievements around the world. With this aim JBUON accepts a broad spectrum of articles such as editorials, original articles, reviews, special articles, short communications, commentaries, letters to the editor and correspondence among authors and readers. JBUON keeps the characteristics of its former paper print edition and appears as a bimonthly e-published journal with continuous volume, issue and page numbers.